Further development led to discovery of a 4,4-difluorocyclohexylamide also known as maraviroc, which preserved excellent antiviral activity, whilst demonstrating no significant hERG binding affinity.
Further development led to discovery of a 4,4-difluorocyclohexylamide also known as maraviroc. Maraviroc preserved excellent antiviral activity, whilst demonstrating no significant hERG binding affinity.